IDEXX Laboratories reports Q3 comparable EPS of $3.96
Q3 comparable EPS was $3.96, versus the FactSet estimate of $3.73.
Related stories
BioMar Group Raises 2026 Revenue and EBIT Guidance, Lowers Volume Outlook
M impact | EARNINGS | Nov 02, 2026, 02:54 PM UTC
BioMar Updates FY2026 EBIT Guidance to DKK 1,290–1,360 Million
M impact | EARNINGS | Nov 02, 2026, 02:46 PM UTC
US Stocks Rise to Kick Off November
US stocks rose at the start of November, with the S&P 500 up 0.5%, the Nasdaq gaining 0.7% and the Dow Jones advancing nearly 400 points, following Friday’s sell-off in AI-related
H impact | EARNINGS | Nov 02, 2026, 02:41 PM UTC
BioMar Updates FY2026 Revenue Guidance to DKK 17.8–18.6 Billion
M impact | EARNINGS | Nov 02, 2026, 02:41 PM UTC
BioMar changes full-year 2026 expectations
BioMar has announced a change to its full-year 2026 expectations.
M impact | EARNINGS | Nov 02, 2026, 02:41 PM UTC
Sygnity Reports Preliminary 9-Month EBITDA of About PLN 102.2 Million
L impact | EARNINGS | Nov 02, 2026, 02:40 PM UTC